Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX EBITDA margin

EBITDA margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
27.2%-2.2pp
Amgen logo
AmgenAMGN
41.5%+3.4pp
Gilead Sciences logo
Gilead SciencesGILD
36.1%+6.2pp
Exelixis logo
ExelixisEXEL
40.6%+6.2pp
CG Oncology logo
CG OncologyCGON
-4,194.4%-1,855pp
Lantheus Holdings logo
Lantheus HoldingsLNTH
23.9%-9.6pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

ebitda/total revenue=-202.5%

Based on trailing twelve months.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's EBITDA margin?
Tango Therapeutics (TNGX) reported EBITDA margin of -202.5% in Q1 2026.
How has Tango Therapeutics's EBITDA margin changed year-over-year?
Tango Therapeutics's EBITDA margin increased by 42.1% year-over-year, from -349.8% to -202.5%.
What is the long-term trend for Tango Therapeutics's EBITDA margin?
Over 4 years (2021 to 2025), Tango Therapeutics's EBITDA margin has grown at a 11.6% compound annual growth rate (CAGR), from -112.6% to -174.7%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.